• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Assessing HeartFlow (HTFL) Valuation After Recent Share Price Weakness

    Simply Wall St·04/01/2026 23:31:07
    Listen to the news

    What HeartFlow’s Recent Trading Tells You

    HeartFlow (HTFL) has drawn attention after a mixed run in recent weeks, with a 0.7% gain over the past day, a 12% decline over the past week, and modest moves over the past month.

    Across a longer window, the stock shows a 16% decline over the past 3 months and a 15% decline year to date. This puts recent price action in focus for investors watching this US$2.1b medical technology name.

    See our latest analysis for HeartFlow.

    With the share price now at US$24.50, the recent 0.7% one-day share price return and 11.7% seven-day share price decline point to fading near-term momentum on top of weaker year-to-date performance.

    If HeartFlow’s recent swings have you thinking about other opportunities in medical AI, it could be a good time to size up 33 healthcare AI stocks

    With HeartFlow trading at US$24.50 against an average analyst price target of US$37.67, the key question is whether this gap reflects undervaluation, or if the market already accounts for its future growth potential.

    Most Popular Narrative: 36.5% Undervalued

    Analysts following HeartFlow see a fair value of $38.60 per share versus the recent $24.50 close, framing a sizeable gap that their narrative tries to explain.

    The transition of HeartFlow Plaque Analysis to a Category 1 CPT code in 2026, with defined Medicare payment rates in both clinic and hospital settings and commercial coverage already at 57% of U.S. lives, sets up a path for more routine clinical use that can add a new revenue stream and support gross margin mix over time.

    Read the complete narrative.

    Analysts are hinging this valuation on a blend of rapid revenue expansion, improving margins, and a rich future earnings multiple that rivals high growth healthcare names. They focus on which specific growth and profitability assumptions need to align for that $38.60 fair value to hold and how sensitive the narrative is to even small changes in those inputs.

    Result: Fair Value of $38.60 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, you also need to weigh the chance that coronary CT adoption or Plaque Analysis uptake slows, which could pressure revenue growth and delay margin improvement.

    Find out about the key risks to this HeartFlow narrative.

    Another Way To Look At Valuation

    While the analyst fair value points to HeartFlow trading at a discount, the current P/S of 11.9x versus 3.3x for peers and a 2.1x industry average tells a different story. Even against a fair ratio of 5.4x, the current level looks rich. How comfortable are you paying that premium?

    See what the numbers say about this price — find out in our valuation breakdown.

    NasdaqGS:HTFL P/S Ratio as at Apr 2026
    NasdaqGS:HTFL P/S Ratio as at Apr 2026

    Next Steps

    Mixed signals or a clear setup: the balance of risks and rewards here is yours to weigh, so check the data, move quickly if you wish, and review the 3 key rewards and 2 important warning signs

    Looking for more investment ideas?

    If HeartFlow has sharpened your thinking, now is the moment to widen your watchlist and line up the next set of stocks to research with purpose.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.